Jan Christoph Simon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jan Christoph Simon has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Anja Saalbach
Department of Allergology, Venerology and Dermatology Leipzig University Leipzig Germany
2 shared publications - Regina Treudler
Institute of Allergology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Deutschland
2 shared publications - Ulf Anderegg
Department of Dermatology, Venereology and Allergology, Leipzig University, Germany
2 shared publications - Andrea A. Robitzki
Centre for Biotechnology and Biomedicine (BBZ), Universität Leipzig, Division of Molecular Biological-Biochemical Processing Technology, Deutscher Platz 5, 04103, Leipzig, Germany.
1 shared publication Andrée Rothermel
Center for Biotechnology and Biomedicine (BBZ), University of Leipzig, Division of Molecular Biological - Biochemical Processing Technology, Deutscher Platz 5, Leipzig, Germany
1 shared publicationAnn-Kristin Picke
Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden 01307, Germany
1 shared publication
Latest Publications
- 1 October 2021
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 27 (19-20) , 1333-1342
Generation of Pigmented Skin Grafts from Human Hair Follicles and Dermal Fibroblasts
Skin equivalents are able to mimic key features of human skin and they can be used for a very broad range of applications, such as fundamental studies of skin biology, disease and toxicological models, as well as an alternative for animal testing. The high end of their use is in therapy of wound healing and repigmentation, disorders that massively affect individual health as well as quality of life and pose considerable burden to healthcare systems worldwide. Tissue-engineered skin grafts often originate from invasively obtained cell material (i.e. biopsy). Hereby, an unmet need for non-invasively gained autologous biological starting material has been created. The hair follicle, entirely non-invasively available by plucking, harbors a heterogeneous cell pool including stem cells with an immense differentiation capacity, hereby representing an attractive source of cells, especially for purposes of regenerative medicine. In this study, we engineered three-dimensional pigmented epidermal and dermoepidermal grafts using human keratinocytes and melanocytes from the outer root sheath of hair follicles combined with dermal fibroblasts. The grafts were generally anatomically correct and functional regarding stratification, formation of epidermal melanin units as well as extracellular matrix deposition, exhibiting moderate differences to the skin anatomy and function, typical for the in vitro culture.
- 1 October 2021
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 27 (19-20) , 1333-1342
Generation of Pigmented Skin Grafts from Human Hair Follicles and Dermal Fibroblasts
Skin equivalents are able to mimic key features of human skin and they can be used for a very broad range of applications, such as fundamental studies of skin biology, disease and toxicological models, as well as an alternative for animal testing. The high end of their use is in therapy of wound healing and repigmentation, disorders that massively affect individual health as well as quality of life and pose considerable burden to healthcare systems worldwide. Tissue-engineered skin grafts often originate from invasively obtained cell material (i.e. biopsy). Hereby, an unmet need for non-invasively gained autologous biological starting material has been created. The hair follicle, entirely non-invasively available by plucking, harbors a heterogeneous cell pool including stem cells with an immense differentiation capacity, hereby representing an attractive source of cells, especially for purposes of regenerative medicine. In this study, we engineered three-dimensional pigmented epidermal and dermoepidermal grafts using human keratinocytes and melanocytes from the outer root sheath of hair follicles combined with dermal fibroblasts. The grafts were generally anatomically correct and functional regarding stratification, formation of epidermal melanin units as well as extracellular matrix deposition, exhibiting moderate differences to the skin anatomy and function, typical for the in vitro culture.
- 30 September 2020
- Published by Springer Nature
- p. 1-8
Diseases with Eosinophilia
- 8 August 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (453)
Thy-1 (CD90) promotes bone formation and protects against obesity
Thy-1 on mesenchymal stem cells promotes osteogenesis while inhibiting adipogenesis and obesity.
- 8 August 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (453)
Thy-1 (CD90) promotes bone formation and protects against obesity
Thy-1 on mesenchymal stem cells promotes osteogenesis while inhibiting adipogenesis and obesity.
- 5 August 2018
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 16 (8) , 1067-1068
In Memoriam Professor Dr. Erwin Schöpf
- 5 August 2018
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 16 (8) , 1067-1068
In Memoriam Professor Dr. Erwin Schöpf
- 27 May 2018
- Published by Springer Nature
- p. 745-752
Hauterkrankungen mit Eosinophilie
- Top Cited Papers
- 19 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (386)
Glycosaminoglycan-based hydrogels capture inflammatory chemokines and rescue defective wound healing in mice
Glycosaminoglycan-based hydrogels scavenge proinflammatory chemokines, reduce the influx of immune cells, and improve the healing of chronic wounds.
- 19 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (386)
Top Cited PapersGlycosaminoglycan-based hydrogels capture inflammatory chemokines and rescue defective wound healing in mice
Glycosaminoglycan-based hydrogels scavenge proinflammatory chemokines, reduce the influx of immune cells, and improve the healing of chronic wounds.
- 7 December 2015
- Published by Springer Nature in Die Dermatologie
- Vol. 67 (2) , 125-131
Arzneimittelnebenwirkungen im Alter
- 7 December 2015
- Published by Springer Nature in Die Dermatologie
- Vol. 67 (2) , 125-131
Arzneimittelnebenwirkungen im Alter
- Open Access
- 6 November 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 1-11
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials. As results of registrational trials might not answer all questions regarding safety and efficacy of ipilimumab in patients with advanced melanoma seen in daily clinical practice, the Dermatologic Cooperative Oncology Group conducted a phase II study to assess the efficacy and safety of ipilimumab in patients with different subtypes of metastatic melanoma. We undertook a multicenter phase II study in melanoma patients irrespective of location of the primary melanoma. Here we present data on patients with pretreated metastatic cutaneous, mucosal and occult melanoma who received up to four cycles of ipilimumab administered at a dose of 3 mg/kg in 3 week intervals. Tumor assessments were conducted at baseline, weeks 12, 24, 36 and 48 according to RECIST 1.1 criteria. Adverse events (AEs), including immune-related AEs were graded according to National Cancer Institute Common Toxicity Criteria (CTC) v.4.0. Primary endpoint was the OS rate at 12 months. 103 pretreated patients received at least one dose of ipilimumab, including 83 cutaneous, seven mucosal and 13 occult melanomas. 1-year OS rates for cutaneous, mucosal and occult melanoma were 38 %, 14 % and 27 %, respectively. Median OS was 6.8 months (95 % CI 5.3–9.9) for cutaneous, 9.6 months (95 % CI 1.6–11.1) for mucosal, and 9.9 months (lower 95 % CI 2.3, upper 95 % CI non-existent) for occult melanoma. Overall response rates for cutaneous, mucosal and occult melanoma were 16 %, 17 % and 11 %, respectively. Eleven patients had partial response (16 %) and ten patients experienced stable disease (14 %), none achieved a complete response. Treatment-related AEs were observed in 71 patients (69 %), including 20 grade 3–4 events (19 %). No new and unexpected safety findings were noted. Ipilimumab is a treatment option for pretreated patients with advanced cutaneous melanoma seen in daily routine. Toxicity was manageable when treated as per protocol-specific guidelines. Trial registration: Clinical Trials.gov NCT01355120
- 6 November 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 1-11
Open AccessOpen-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials. As results of registrational trials might not answer all questions regarding safety and efficacy of ipilimumab in patients with advanced melanoma seen in daily clinical practice, the Dermatologic Cooperative Oncology Group conducted a phase II study to assess the efficacy and safety of ipilimumab in patients with different subtypes of metastatic melanoma. We undertook a multicenter phase II study in melanoma patients irrespective of location of the primary melanoma. Here we present data on patients with pretreated metastatic cutaneous, mucosal and occult melanoma who received up to four cycles of ipilimumab administered at a dose of 3 mg/kg in 3 week intervals. Tumor assessments were conducted at baseline, weeks 12, 24, 36 and 48 according to RECIST 1.1 criteria. Adverse events (AEs), including immune-related AEs were graded according to National Cancer Institute Common Toxicity Criteria (CTC) v.4.0. Primary endpoint was the OS rate at 12 months. 103 pretreated patients received at least one dose of ipilimumab, including 83 cutaneous, seven mucosal and 13 occult melanomas. 1-year OS rates for cutaneous, mucosal and occult melanoma were 38 %, 14 % and 27 %, respectively. Median OS was 6.8 months (95 % CI 5.3–9.9) for cutaneous, 9.6 months (95 % CI 1.6–11.1) for mucosal, and 9.9 months (lower 95 % CI 2.3, upper 95 % CI non-existent) for occult melanoma. Overall response rates for cutaneous, mucosal and occult melanoma were 16 %, 17 % and 11 %, respectively. Eleven patients had partial response (16 %) and ten patients experienced stable disease (14 %), none achieved a complete response. Treatment-related AEs were observed in 71 patients (69 %), including 20 grade 3–4 events (19 %). No new and unexpected safety findings were noted. Ipilimumab is a treatment option for pretreated patients with advanced cutaneous melanoma seen in daily routine. Toxicity was manageable when treated as per protocol-specific guidelines. Trial registration: Clinical Trials.gov NCT01355120